According to Prof P Manokar, cardiologist, discontinuing cholesterol therapy mid-course could quickly result in an elevation in low-density lipoprotein (LDL), putting one at greater risk of myocardial infarction, ischaemic stroke, and other forms of vascular damage. Cessation of the therapy will disrupt any potential stability and allow the underlying risk factors to resurface.